Acellular Therapy
| Consolidated income statement | | | | | | | For the year ended December 31 | | | 2020 | | 2019 | | | Thousands of dollars | | Thousands of dollars | | income | 390,846 | | 273,354 | | Cost of sales | (134,953) | | (93,064) | | gross profit | 255,893 | | 180,290 | | Other income and gains | 24,795 | | 21,185 | | Selling and distribution expenses | (107,341) | | (70,358) | | Administrative expenses | (90,341) | | (55,256) | | R&D expenditure | (263,401) | | (186,022) | | Fair value loss of convertible redeemable preferred shares | (79,984) | | — | | Financing costs | (5,432) | | (781) | | Other expenses | (15,497) | | (589) | | Share of losses of associates | (599) | | (308) | | Net reversal/(provision) of impairment of financial assets | 7 | | (1,851) | | Loss before tax | (281,900) | | (113,690) | | Income tax credit/(expense) | 477 | | (3,826) | | Loss during the year | (281,423) | | (117,516) | | The following persons should be accounted for: Owners of the parent company | (204,945) | | (96,912) | | Non-controlling interest | (76,478) | | (20,604) | | | (281,423) | | (117,516) | | Consolidated statement of financial position | | | | | | | For the year ended December 31 | | | 2020 | | 2019 | | Non-current assets | Thousands of dollars | | Thousands of dollars | | Property, plant and equipment | 345,215 | | 235,986 | | Advance payment for property, plant and equipment | 5,906 | | 8,585 | | Investment property | 7,726 | | 7,442 | | Right-of-use asset | 34,017 | | 29,642 | | Goodwill | 14,116 | | 15,245 | | Other intangible assets | 26,020 | | 25,482 | | Investment in associates | 3,433 | | 2,615 | | Financial assets that are measured at fair value and whose changes are included in profit or loss | 10,555 | | 4,667 | | Other non-current assets | 3,542 | | — | | Deferred tax assets | 3,702 | | 5,701 | | Total non-current assets | 454,232 | | 335,365 | | Current assets | | | | | stock | 31,745 | | 16,486 | | Contract cost | 5,785 | | 3,369 | | Trade receivables and bills receivable | 141,748 | | 73,067 | | Prepayments, other receivables and other assets | 32,834 | | 31,621 | | Financial assets that are measured at fair value and whose changes are included in profit or loss | 5,866 | | 25,434 | | Loans made to associates | 2,422 | | 2,007 | | Restricted cash | 7,471 | | 972 | | Time deposit | 136,245 | | 148,693 | | Cash and cash equivalents | 629,058 | | 252,397 | | Total current assets | 993,174 | | 554,046 | | | For the year ended December 31 | | | 2020 | | 2019 | | Current liabilities | Thousands of dollars | | Thousands of dollars | | Trade payables and bills payable | 23,376 | | 17,627 | | Other payables and accrued expenses | 168,980 | | 125,035 | | Interest-bearing bank loans | 44,642 | | 17,008 | | Lease liability | 2,588 | | 1,769 | | Tax payable | 3,532 | | 2,846 | | Contract liabilities | 84,414 | | 60,130 | | government subsidy | 379 | | 90 | | Total current liabilities | 327,911 | | 224,505 | | Net current assets | 665263 | | 329,541 | | Total assets minus current liabilities | 1,119,495 | | 664,906 | | Non-current liabilities | | | | | Interest-bearing bank loan | 1,260 | | 1,748 | | Lease liability | 6,513 | | 3,608 | | Contract liabilities | 277,052 | | 277,827 | | Deferred tax liabilities | 7,030 | | 5,582 | | government subsidy | 11,495 | | 3,843 | | Other non-current liabilities | 554 | | — | | Total non-current liabilities | 303,904 | | 292,608 | | Net assets | 815,591 | | 372,298 | | rights and interests | | | | | Equity attributable to owners of the parent company | | | | | Equity | 1,954 | | 1,879 | | Treasury shares | (16,712) | | (7,774 | | reserve | 916,463 | | 388,699 | | | 901,705 | | 382,804 | | Non-controlling interest | (86,114) | | (10,506 | | Total equity | 815,591 | | 372,298 |
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
|
